The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion (given directly into a vein) or subcutaneous injection (given under the skin). The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause.

Throughout the study, doctors will monitor patients’ health, check how well the treatment is working, and track any side effects. They will look at how many patients respond to treatment and how long the response lasts. For some patients, they will also measure the amount of cancer cells remaining in the blood or bone marrow after treatment.

Participants in the study will receive different types of medicine. Some medications, such as glofitamab, rituximab, and bendamustine, are given through an IV infusion, which is a method of delivering medicine directly into a vein. Other medicines, such as lenalidomide, are taken as capsules by mouth. During the study, doctors will monitor how the cancer responds to the treatment and track how long the disease remains stable without getting worse, a measure known as progression-free survival.

Participants in the study will receive the treatment through an intravenous method, which means the medication is given directly into a vein. The study will follow the participants over a period to observe the effects of the treatment on their condition. The main goal is to assess how long patients can go without their disease getting worse after receiving the treatment. The study will also look at other outcomes, such as overall survival, which is the length of time patients live after starting the treatment, and the rate at which patients’ conditions improve or stabilize.

Throughout the study, researchers will monitor for any side effects or adverse events that may occur. This information will help determine the safety and effectiveness of loncastuximab tesirine as a treatment option for patients with relapsed or refractory Mantle Cell Lymphoma. The study is designed to provide valuable insights into whether this treatment can offer a new option for patients who have limited choices due to their previous treatments.

The purpose of the study is to assess how effective this treatment is in patients whose cancer has returned or has not responded to previous treatments. Participants in the study will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

The study will take place over a period of time, during which participants will be closely monitored by healthcare professionals. This monitoring will include regular check-ups and tests to evaluate the response to the treatment and to ensure the safety of the participants. The study aims to provide valuable information on the potential benefits and risks of using Brexucabtagene Autoleucel for treating Relapsed/Refractory Mantle Cell Lymphoma.

The study is divided into two parts. In the first part, the main goal is to determine how safe and tolerable BGB-11417 is for patients, and to find the best dose to use in the second part of the study. The second part aims to assess how well the treatment works at the recommended dose. Patients will take the medication orally, and the study will monitor their response to the treatment over time.

Throughout the study, researchers will collect information on any side effects experienced by participants and how the drug affects their health. The trial will also look at how the drug is processed in the body, which is known as pharmacokinetics. This information will help determine if BGB-11417 is a suitable treatment option for patients with Mantle Cell Lymphoma that has relapsed or is refractory, meaning it has not responded to other treatments.

The purpose of the study is to evaluate how effective the KTE-X19 therapy is in treating patients who have shown a partial response to Ibrutinib treatment. During the study, patients will first receive Ibrutinib to manage their condition. If they achieve a partial response, they will then receive the KTE-X19 therapy. This involves an infusion, which is a way of delivering the treatment directly into the bloodstream. The study will monitor patients for a period of time to assess the response to the treatment and any potential side effects.

In addition to KTE-X19 and Ibrutinib, the study may also involve other medications such as Cyclophosphamide and Fludarabine, which are chemotherapy agents used to prepare the body for the cell therapy. The trial aims to provide insights into the effectiveness of this combination of treatments in managing Mantle Cell Lymphoma and improving patient outcomes. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the treatment’s impact on their condition.